Home
About
FAQ
History (34)
Use of an electrocardiographic screening tool to determine candidacy for a subcutaneous implantable cardioverter-defibrillator.
Hydrogen sulfide, then nitric oxide and vasoprotection.
Determination of qualitative telomerase activity as an adjunct to the diagnosis of pancreatic adenocarcinoma by EUS-guided fine-needle aspiration.
Bladder Hydrodistention Does Not Result in a Significant Change in Bladder Capacity for Interstitial Cystitis/Bladder Pain Syndrome Patients.
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control.
See All 34 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control.
Rikhi R, Shapiro MD. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: The Big Step Forward in Lipid Control. Eur Cardiol. 2023; 18:e45.
View in:
PubMed
authors with profiles
Michael D. Shapiro DO, MCR